[Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D002225:Carbazilquinone / Q000494:pharmacology; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005047:Etoposide / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000494:pharmacology; D013852:Thiotepa / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D000970:Antineoplastic Agents; D008937:Mitomycins; D009607:Nitrosourea Compounds; D015376:Nimustine; D001761:Bleomycin; D002225:Carbazilquinone; D016685:Mitomycin; D005047:Etoposide; D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin